Does testosterone or estrogen control bone density in men?

Estradiol is the dominant hormonal regulator of bone density in adult men, and testosterone contributes largely by serving as the substrate that aromatase converts into estradiol. The evidence comes from three directions: men with estrogen receptor alpha mutations who have low bone density despite normal testosterone, men with aromatase deficiency whose bone density improves when given estrogen, and controlled studies that suppressed endogenous hormones and replaced testosterone with and without an aromatase blocker. In that last design, bone outcomes tracked estradiol rather than testosterone. Direct androgen receptor signalling still contributes, but it is the smaller of the two hormonal inputs.

What is a normal DEXA T-score for a man?

A T-score of -1.0 or higher is classified as normal bone density, a score between -1.0 and -2.5 is osteopenia or low bone mass, and a score of -2.5 or lower meets the diagnostic threshold for osteoporosis. T-scores compare a man against young adult peak bone mass and are the appropriate score for men aged 50 and over. Men under 50 are read by Z-score instead, which compares them against men of the same age, with a Z-score of -2.0 or lower described as below the expected range for age. Any fragility fracture from a low-energy fall indicates osteoporosis regardless of what the score shows.

Should men get bone density scans?

There is no universal screening recommendation for men, since the United States Preventive Services Task Force has judged the evidence insufficient to recommend for or against routine screening. Endocrine Society guidance nonetheless points to scanning men aged 70 and older, men aged 50 to 69 with risk factors, and men of any age with hypogonadism, a prior fragility fracture, long-term glucocorticoid use, or androgen deprivation therapy. Because the scan is not automatic, a man who wants a baseline generally has to request it. The decision about whether it is indicated belongs with a physician who knows the full history.

Do aromatase inhibitors cause bone loss in men?

Aromatase inhibitors reduce estradiol, and reduced estradiol accelerates bone resorption in men through increased osteoclast activity in the RANKL and osteoprotegerin pathway. The clearest evidence comes from oncology, where accelerated bone loss and higher fracture rates in patients on aromatase inhibitors or androgen deprivation therapy led to bone monitoring being built into the treatment protocols. A man using an aromatase inhibitor as part of a hormone protocol is exposed to the same mechanism, usually without the monitoring. Whether an aromatase inhibitor is appropriate is a physician decision based on symptoms and laboratory results together.

How much does testosterone therapy improve bone density?

In the bone component of the Testosterone Trials, published by Snyder and colleagues in JAMA Internal Medicine in 2017, men aged 65 and older with low testosterone who received one year of testosterone gel showed roughly a 7.5 percent greater increase in spine trabecular volumetric bone mineral density than men on placebo, measured by quantitative CT. Gains at the hip and in cortical bone were smaller. The trial ran for 12 months and was not powered to detect fractures, so the improvement is a density result rather than proof of fewer broken bones. Testosterone is a prescription medication and this is not a reason to seek it without a diagnosis.

Does losing weight on a GLP-1 hurt your bones?

Bone mineral density falls during substantial weight loss regardless of the method used, with reported losses around 1 to 2 percent per year at the hip during active weight reduction. Mechanical unloading and reduced nutrient intake both contribute. Since GLP-1 receptor agonists now commonly produce 15 to 20 percent total body weight reduction, the same concern applies, and bone was not a primary endpoint in the major trial programmes. The countermeasures are progressive resistance training, protein intake toward 1.2 to 1.6 grams per kilogram daily, and adequate calcium and vitamin D, all of which also protect the lean mass that is lost alongside the fat.

What exercise builds bone density in men over 40?

Bone adapts to high-magnitude, rapidly applied loads that exceed the strain it customarily experiences, which means heavy compound resistance work and impact exposure rather than steady-state cardio. The LIFTMOR-M trial published by Harding and colleagues in 2020 used eight months of supervised twice-weekly high-intensity resistance and impact training in men with low bone mass and reported improvements in lumbar spine bone mass and hip geometry. Walking and cycling provide little osteogenic stimulus, and competitive male cyclists have repeatedly been reported to carry lower spine bone density than sedentary controls. Supervision matters, because the same movements performed with poor technique are a common injury route in older men.

How often should a bone density scan be repeated?

Meaningful change in bone mineral density usually takes 12 to 24 months to appear, so rechecking sooner than a year rarely produces interpretable information. Repeat intervals in practice range from one to several years depending on the baseline result, the presence of risk factors, and whether treatment has been started. Comparisons are most reliable when performed on the same scanner, since equipment differences introduce variation that can be mistaken for real change. The interval is a physician decision rather than a fixed rule.

testosterone24

Bone Density in Men: Why Estradiol Runs the Skeleton and What a DEXA Scan Shows After 40

Back to Articles

Hormones 13 min read Aug 22, 2026

Bone Density in Men: Why Estradiol Runs the Skeleton and What a DEXA Scan Shows After 40

Osteoporosis is filed as a women's condition, which is why the men who have it usually find out in an emergency room.

Ask most men over 40 what their bone density is and you get a blank look. Ask them their testosterone number and many can quote it to the decimal. That asymmetry is strange, because the hormone that governs the male skeleton is not the one men track. It is estradiol, converted from testosterone by aromatase, and the men most likely to be suppressing it are the men on hormone protocols who believe they are optimizing. Meanwhile the scan that would show the damage is ordered for women almost by default and for men almost never.

Male osteoporosis is not rare and it is not mild. Roughly one in four men over 50 will break a bone because of low bone density at some point in the rest of his life, and men account for close to a third of all hip fractures. The outcome after that fracture is worse for men than for women. Reported one-year mortality after a hip fracture in men sits near 30 percent in multiple cohort analyses, roughly double the figure usually cited for women of the same age. The condition is not gender-neutral in its consequences, only in the attention it receives.

The reason men go undiagnosed is structural. The United States Preventive Services Task Force has repeatedly issued an I statement for osteoporosis screening in men, meaning the evidence is judged insufficient to recommend for or against routine screening. An I statement is not a finding that screening fails. It is a finding that nobody has run the trial. In practice it means the scan is not automatic, so a man who wants a baseline has to ask for it by name, the same way he has to ask for ApoB rather than assume it appears on a lipid panel.

Estradiol

The dominant hormonal regulator of bone in men, not testosterone

Testosterone contributes largely after aromatase converts it to estradiol, which then acts on estrogen receptor alpha in bone

1 in 4

Men over 50 who will sustain an osteoporosis-related fracture in their remaining lifetime

Men also make up close to a third of hip fractures and have roughly double the one-year post-hip-fracture mortality of women

-2.5

The DEXA T-score at or below which osteoporosis is diagnosed

A T-score between -1.0 and -2.5 is osteopenia, and men under 50 are read by Z-score rather than T-score

7.5%

Increase in spine trabecular volumetric bone density over 12 months of testosterone gel in the Testosterone Trials bone study

Snyder and colleagues, JAMA Internal Medicine 2017, in men aged 65 and older with low testosterone; the trial was not powered for fracture outcomes

20 pg/mL

The approximate total estradiol threshold below which reported bone loss accelerates in older men

Drawn from observational cohorts including the MrOS study; thresholds vary by assay and by whether total or bioavailable estradiol is measured

1 to 2%

Typical annual bone mineral density loss reported during rapid weight loss without resistance training

Relevant to men losing weight quickly on GLP-1 therapy, where bone and lean mass are lost alongside fat unless loading and protein intake are maintained

What actually controls bone density in men?

Estradiol is the dominant hormonal regulator of the adult male skeleton, and testosterone contributes to bone mostly by serving as the substrate that aromatase converts into estradiol. This is counterintuitive enough that it took clinical accidents to establish it. In 1994 Smith and colleagues described in the New England Journal of Medicine a man with a mutation in the estrogen receptor alpha gene who had normal or elevated testosterone, unfused growth plates in adulthood, and markedly low bone density. Testosterone was present and functioning at the androgen receptor. Bone still failed, because the estrogen signal never arrived.

Cases of aromatase deficiency told the same story from the other direction. Men who cannot convert testosterone to estradiol present with tall stature, open epiphyses, and low bone mass despite high androgen levels, and treating them with estrogen closes the growth plates and increases bone mineral density. Carani and colleagues published exactly that sequence in the New England Journal of Medicine in 1997. The androgen was never the missing ingredient.

The controlled experiment came later. Finkelstein and colleagues, publishing in the New England Journal of Medicine in 2013 and in follow-up bone analyses from the same program, suppressed endogenous hormone production in healthy men with a GnRH agonist, then replaced testosterone across a range of doses, with half the participants also receiving anastrozole to block aromatization. That design separates androgen effects from estrogen effects in the same men. Bone resorption markers and bone density outcomes tracked estradiol, not testosterone. The men receiving testosterone without the ability to aromatize it lost bone.

Relative Contribution to Adult Male Bone Maintenance by Signal (Illustrative Weighting)

What does a DEXA scan actually measure?

A DEXA scan measures areal bone mineral density in grams per square centimetre by passing two X-ray energies through the skeleton and calculating how much each tissue absorbs. The standard clinical scan reports the lumbar spine, the femoral neck, and the total hip, and some protocols add the distal radius when the spine is unreadable due to arthritis or previous surgery. Radiation exposure is very low, generally below the dose of a transatlantic flight, and the scan takes about ten minutes with no injection or preparation beyond removing metal.

The raw density number is then converted into two scores that mean different things. A T-score compares the result against the mean peak bone density of a young adult reference population. A Z-score compares it against the mean for men of the same age. The distinction matters clinically because a 45-year-old with a T-score of -1.8 is being compared against 30-year-olds, while his Z-score tells his physician whether he is unusual for his own age group, which is the question that prompts a search for a secondary cause.

How DEXA Results Are Classified in Men

Result	Definition	Which Score Applies	What It Usually Prompts
Normal bone density	T-score of -1.0 or higher at spine, femoral neck, and total hip	T-score, for men aged 50 and older	Repeat interval decided by risk factors rather than by the scan itself, often several years
Osteopenia, or low bone mass	T-score between -1.0 and -2.5	T-score, for men aged 50 and older	A search for reversible causes, attention to loading and nutrition, and a fracture risk calculation such as FRAX
Osteoporosis	T-score of -2.5 or lower, or any fragility fracture regardless of score	T-score, for men aged 50 and older	A full secondary workup and a physician discussion about pharmacological treatment
Below the expected range for age	Z-score of -2.0 or lower	Z-score, the preferred score for men under 50	Investigation of secondary causes, since low bone mass at a younger age is rarely idiopathic
Within the expected range for age	Z-score above -2.0	Z-score, for men under 50	Reassurance about age-relative standing, which does not rule out a low absolute density worth improving

One limitation is worth knowing before reading a report. Areal density measured by DEXA is influenced by bone size, so larger-framed men can score better than their true volumetric density warrants and smaller-framed men can score worse. Degenerative changes in the lumbar spine, aortic calcification, and old fractures also inflate spine readings in older men, which is why the hip is often treated as the more reliable site after 60. Quantitative CT measures volumetric density and avoids the size artifact, but it carries more radiation and is used mainly in research settings.

When should a man get a DEXA scan?

Endocrine Society guidance points to scanning men aged 70 and older, men aged 50 to 69 who carry risk factors, and men of any age with hypogonadism, a fragility fracture, long-term glucocorticoid use, or androgen deprivation therapy. Because there is no universal screening recommendation for men, the scan usually happens only when a man or his physician raises it deliberately. A baseline taken while a man is healthy is also more useful than a first scan taken after a fracture, since bone density is interpreted best as a trend.

Diagnosed or suspected hypogonadism

Low testosterone in men means low estradiol downstream, and bone loss is one of the recognised consequences of untreated hypogonadism rather than a rare complication

Any use of an aromatase inhibitor

Anastrozole and similar drugs suppress the exact signal that maintains male bone, and men taking them for hormone protocols often have no scan and no monitoring in place

Rapid or large weight loss

Bone mineral density falls alongside fat and lean mass during aggressive weight loss, which is increasingly relevant for men losing 15 percent or more of body weight on GLP-1 therapy

Long-term glucocorticoid exposure

Oral steroids taken for more than three months are among the strongest secondary causes of bone loss in men, and inhaled high-dose regimens are not automatically neutral either

A fracture from a fall at standing height

A break from a low-energy fall after 50 is classified as a fragility fracture and by itself signals osteoporosis regardless of what the T-score says

Heavy alcohol intake or current smoking

Both suppress bone formation and both appear as independent inputs in the FRAX fracture risk calculator alongside age, weight, and prior fracture

Endurance training without any loading

Cycling and swimming provide almost no osteogenic stimulus, and competitive male cyclists have repeatedly been reported to carry lower spine bone density than matched sedentary controls

Does testosterone therapy increase bone density?

Testosterone therapy increases bone mineral density in men with low testosterone, and the best evidence comes from the bone component of the Testosterone Trials. Snyder and colleagues, publishing in JAMA Internal Medicine in 2017, randomized men aged 65 and older with unequivocally low testosterone to one year of testosterone gel or placebo, using quantitative CT rather than DEXA alone. Spine trabecular volumetric bone mineral density rose by roughly 7.5 percent more in the testosterone group than in placebo, with smaller gains at the hip and in cortical bone.

That result comes with an important limit. The trial measured density over 12 months and was never designed or powered to show fewer fractures, which is the outcome that actually matters to a man. Density is a surrogate. It correlates with fracture risk across populations, but no testosterone trial to date has demonstrated fracture reduction, and honest reporting of the evidence says so. The mechanism is also consistent with everything above, since testosterone gel raises estradiol through aromatization alongside the androgen itself.

Illustrative Trajectory of Lumbar Spine Bone Density Under Different Conditions Over 24 Months

Untreated hypogonadism, no loading programme
Untreated, but training with progressive resistance work
Physician-managed testosterone therapy alone
Physician-managed therapy plus resistance and impact loading

The curves above are constructed illustrations of direction rather than measured data from any single study, and no individual should expect his own scan to follow them. They are drawn to make one point visible. Loading and hormonal status act through different pathways, so their contributions are not redundant, and the slowest line is the one where neither input is present. A man who fixes his hormones and never touches a barbell is using one of the two largest levers available to him.

Why does suppressing estradiol damage male bone?

Suppressing estradiol removes the brake on bone resorption. Estrogen signalling through estrogen receptor alpha restrains osteoclast activity and promotes osteoclast apoptosis, largely through the RANKL and osteoprotegerin system. When estradiol falls, RANKL activity rises relative to osteoprotegerin, osteoclasts live longer and work harder, and resorption outpaces formation. The net result is bone loss that shows up in resorption markers within weeks and in density measurements over years.

This is why aromatase inhibitor use in men is a serious decision rather than a routine add-on. The clearest evidence comes from oncology, where men on androgen deprivation therapy and women on adjuvant aromatase inhibitors both experience accelerated bone loss and elevated fracture rates, which is precisely why bone monitoring is built into those treatment protocols. A man taking anastrozole informally to keep his estradiol low is running a version of the same experiment on himself without the monitoring that oncology considers mandatory.

The Number That Gets Crushed on Purpose

Among men on hormone protocols, estradiol is the value most often deliberately driven down, usually to avoid water retention or breast tissue sensitivity. Those side effects are real and treatable, and an aromatase inhibitor prescribed by a physician for a specific indication is a legitimate tool. What is not legitimate is the reflexive protocol that adds an aromatase inhibitor from day one, targets an estradiol level far below the range seen in healthy young men, and never orders a bone scan. Estradiol in men is not a contaminant of testosterone therapy. It is the signal that maintains the skeleton, supports HDL cholesterol, and contributes to libido and cognition. Observational cohorts including the MrOS study suggest bone loss accelerates once total estradiol falls below roughly 20 pg/mL, though assay differences and the choice between total and bioavailable estradiol move that number around. Any decision to use an aromatase inhibitor belongs with a physician who is also monitoring the consequences.

How does rapid weight loss affect bone density?

Weight loss reduces bone mineral density, and the faster and larger the loss, the more bone tends to go with it. Reported figures cluster around 1 to 2 percent of hip bone density lost per year during active weight reduction, with steeper losses after bariatric surgery. Mechanical unloading explains part of it, since a lighter skeleton experiences smaller forces, and reduced energy and calcium intake explains more. Weight regain does not reliably restore what was lost.

This has become directly relevant to men on GLP-1 receptor agonists, where total body weight reductions of 15 to 20 percent are now common over a year. The trials for these drugs were designed around cardiometabolic endpoints, not skeletal ones, and bone density was not a primary outcome in the major programmes. The practical response is not to avoid the therapy but to protect the tissue that is at risk, which means resistance training that progresses in load, protein intake toward the upper end of the usual recommendations, and adequate calcium and vitamin D. The same countermeasures protect lean mass, which is the other thing being lost.

Where a Man Over 40 Can Actually Influence His Bone Density (Illustrative Allocation of Modifiable Inputs)

Progressive resistance and impact loading of the hip and spine
Keeping estradiol in a physiological range rather than suppressed
Protein, calcium, and vitamin D intake sufficient for bone turnover
Avoiding rapid unsupported weight loss and heavy alcohol intake
Identifying and treating secondary causes such as steroid use or coeliac disease

That allocation covers only what a man can change, which is why it excludes age, genetics, and peak bone mass reached in his twenties. Those set the starting point and cannot be renegotiated. The modifiable share is still large enough to matter, particularly because the two biggest slices are cheap and available to almost everyone reading this.

What kind of training actually builds bone?

Bone responds to high-magnitude, rapidly applied, unusual loads rather than to duration or repetition. This is the practical translation of the mechanostat model, which holds that bone adapts to strain that exceeds a customary threshold and does nothing in response to strain it already experiences daily. Walking is good for many things and does very little for the femoral neck of a man who already walks. Heavy compound lifting and impact work do something walking cannot.

The LIFTMOR-M trial, published by Harding and colleagues in 2020, tested this in men with low bone mass using eight months of supervised high-intensity resistance and impact training performed twice weekly. Deadlifts, overhead press, squats, and jumping chin-up drops with drop landings produced improvements in lumbar spine bone mass and hip geometry compared with a control programme. The protocol was supervised, progressed carefully, and reported no significant adverse events, which matters because the same movements performed badly in an unsupervised setting are how men over 50 injure themselves.

The Order That Makes Bone Work Actually Productive

Get the Baseline Scan

Request a DEXA and read both the T-score and the Z-score, since a scan taken after a fracture cannot tell you what your density was before it

→

↓

Rule Out Secondary Causes

Low bone mass in a man under 60 is usually secondary to something identifiable, so hormones, vitamin D, calcium, coeliac screening, and medication review come before any treatment decision

→

↓

Stop Actively Losing Bone

Address the inputs currently working against you, whether that is a suppressed estradiol level, a very rapid weight loss trajectory, heavy alcohol intake, or unmonitored glucocorticoid use

→

↓

Load the Skeleton Deliberately

Add progressive resistance work targeting hip and spine plus impact exposure, learning technique under supervision before chasing load, since bone adapts to strain above its customary threshold

A First-Year Structure to Discuss With a Physician

Months 1 to 2

✓Request a DEXA scan of lumbar spine, femoral neck, and total hip, and ask for both T-score and Z-score to be reported rather than one summary line
✓Draw total testosterone, sensitive estradiol, vitamin D as 25-hydroxyvitamin D, calcium, and parathyroid hormone at the same visit, since the workup is more useful read together
✓List every current medication with the physician, including any aromatase inhibitor, glucocorticoid, proton pump inhibitor, or anticonvulsant, because several of these affect bone
✓Record height accurately, since a loss of more than 4 centimetres from peak adult height can indicate vertebral compression that no one has diagnosed

Months 3 to 6

✓Revisit any estradiol suppression with the prescribing physician, since a level well below the healthy young male range is a modifiable cause of ongoing bone loss
✓Bring protein intake toward 1.2 to 1.6 grams per kilogram of body weight daily, an amount associated with better bone and lean mass retention in older adults
✓Correct a low vitamin D level under physician guidance and get calcium primarily from food, since the trial evidence for high-dose calcium supplements is mixed and not risk-free
✓Begin supervised resistance training focused on hip and spine loading, spending the first several weeks on technique at moderate load rather than pushing weight early

Months 7 to 12

✓Progress loading in small increments, since bone responds to strain that exceeds its customary threshold and a programme that never gets heavier stops being a stimulus
✓Add impact exposure appropriate to joint health and training history, working up from low-amplitude hops rather than starting with drop landings
✓If losing weight on GLP-1 therapy or any aggressive deficit, hold resistance training and protein intake constant throughout, since these are what protect bone and lean mass during the loss
✓Discuss the timing of a repeat DEXA with the physician, keeping in mind that meaningful density change usually needs 12 to 24 months and ideally the same scanner for comparability

What should a man take away from all this?

The takeaway is that male bone density is governed by a hormone most men on protocols are actively suppressing, measured by a scan most men never receive, and defended by training most men over 40 have abandoned in favour of cardio. Estradiol converted from testosterone is the primary hormonal maintainer of the male skeleton, established through receptor mutation cases, aromatase deficiency cases, and the controlled hormone-suppression work of Finkelstein and colleagues. Testosterone therapy raises bone density in men who are genuinely deficient, with the Testosterone Trials bone study reporting a 7.5 percent gain in spine trabecular density over a year, though no trial has yet shown fracture reduction. A DEXA baseline costs little, involves minimal radiation, and gives a comparison point that becomes impossible to reconstruct later. None of that replaces a physician, and all of it makes the conversation with one more specific.

Medical Disclaimer

This article is for educational purposes only and is not medical advice. Nothing here diagnoses, treats, cures, or prevents any disease, including osteoporosis, osteopenia, or hypogonadism. Testosterone and aromatase inhibitors are prescription medications in most jurisdictions and decisions to start, adjust, or stop them must be made with a licensed physician who knows your full medical history. GLP-1 receptor agonists are prescription medications and are not appropriate for self-directed use. The charts, weightings, and trajectory curves shown here are illustrative demonstrations of direction rather than study results, pooled analyses, or predictions about any individual, and the trials referenced differ in population, age range, dose, and duration so their figures are not directly comparable. Diagnostic thresholds, laboratory reference ranges, and scanner calibration vary between institutions and between clinical guidelines. Speak with a licensed healthcare professional about bone density testing, your bloodwork, and your medical history before making any decision.